Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to -$59.1 million.

  • Bicycle Therapeutics' Net Income towards Common Stockholders fell 1633.4% to -$59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.7 million, marking a year-over-year decrease of 5074.94%. This contributed to the annual value of -$169.0 million for FY2024, which is 643.9% up from last year.
  • Bicycle Therapeutics' Net Income towards Common Stockholders amounted to -$59.1 million in Q3 2025, which was down 1633.4% from -$79.0 million recorded in Q2 2025.
  • Bicycle Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$14.7 million during Q3 2021, with a 5-year trough of -$79.0 million in Q2 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$39.1 million (2023), whereas its average is -$38.3 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 3200.13% in 2024, then plummeted by 12871.66% in 2025.
  • Bicycle Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$18.0 million in 2021, then tumbled by 66.2% to -$30.0 million in 2022, then crashed by 63.78% to -$49.1 million in 2023, then fell by 5.61% to -$51.9 million in 2024, then fell by 13.97% to -$59.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$59.1 million in Q3 2025, compared to -$79.0 million in Q2 2025 and -$60.8 million in Q1 2025.